NCT06585202

Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 2a Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of ATI-2138 Administered Over 12 Weeks in Participants With Moderate to Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Aclaris Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.

Detailed description

This open-label, single-arm study of ATI-2138 in moderate to severe AD participants between the ages of 18 and 60 years (inclusive) will investigate the safety, tolerability, pharmacokinetics, efficacy and pharmacodynamics of ATI-2138 administered over 12 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	ATI-2138	ATI-2138 Oral Tablets BID

Timeline

• Start date: 2024-08-19
• Primary completion: 2025-03-13
• Completion: 2025-03-31
• First posted: 2024-09-05
• Last updated: 2026-03-12

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study